FFR-Guided Intervention Improves Patient Outcomes in Belgium, Saves Millions of Euros

Strategic Insights -

A study funded by St. Jude Medical found that using Fractional Flow Reserve (FFR)-guided intervention in Belgium to determine the severity of blood flow blockages in patients' coronary arteries can lead to improved patient outcomes and significant cost savings. The analysis, which utilized original data from the landmark FAME study, demonstrated that the FFR-guided approach is cost-saving and can prevent thousands of avoidable deaths, heart attacks, and major adverse cardiac events (MACE) in Belgium over two years.

Key Takeaways:

  • The FFR-guided approach can prevent, on average, more than 60 avoidable deaths, more than 140 heart attacks, and more than 245 major adverse cardiac events (MACE) in Belgium over two years.
  • The use of PressureWire technology can save the Belgian healthcare system nearly 4 million Euros over two years.
  • The FFR-guided strategy reduces treatment cost by an average of 950 per patient in Belgium for Percutaneous Coronary Intervention (PCI).
  • The study found that FFR measurements can improve quality-adjusted life expectancy for Belgian PCI patients.
  • The PressureWire technology is recognized as a standard of care for patients with multivessel coronary disease in the context of the Belgian healthcare system.

Statistics:

  • 60 avoidable deaths prevented in Belgium over two years.
  • 140 heart attacks prevented in Belgium over two years.
  • 245 major adverse cardiac events (MACE) prevented in Belgium over two years.
  • 4 million Euros saved by the Belgian healthcare system over two years.
  • 950 Euros saved per patient in Belgium for Percutaneous Coronary Intervention (PCI).

Sources:

  • St. Jude Medical, Inc. (2013). Analysis Reveals FFR-Guided Intervention in Belgium Saves Millions.
  • FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) study.
  • New England Journal of Medicine (2009). FAME study 12-month results.
  • Transcatheter Cardiovascular Therapeutics (TCT) Conference (2009). FAME study two-year results.